Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-914392 in Paroxysmal Atrial Fibrillation
NCT01356914Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-914392 in Atrial fibrillation (AFib) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Atrial Fibrillation Burden at Day 22. Started May 2011; status: completed.
02
Drugs
BMS-914392
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01356914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356914.